Helsinn Healthcare and Vifor Pharma, a company of Galenica, have entered into an exclusive licence and distribution agreement for netupitant-palonosetron fixed-dose combination, NEPA, a Helsinn product currently in the development stage for the treatment of chemotherapy-induced nausea and vomiting. Under the agreement, Vifor Pharma will have rights to distribute the product in Switzerland, France, Spain, Portugal, the Netherlands, Belgium and Luxembourg. Vifor Pharma will also assume responsibility for registering the product in Switzerland.
|Agreement Status:||New||Date Announced:||16 May 2013|
|Date Last Reported:||Duration:|
|Est Total Value:||Investment To Date:|
|Agreement Type:||Commercialisation Distribution|
|Generic / Brand Name:||netupitant palonosetron|
|Therapeutic Area:||Central Nervous System|
|Indication:||Vomiting and nausea associated with chemotherapy|